Validation of Analytic Methods for Biomarkers Used in Drug Development

The role of biomarkers in drug discovery and development has gained precedence over the years. As biomarkers become integrated into drug development and clinical trials, quality assurance and, in particular, assay validation become essential with the need to establish standardized guidelines for analytic methods used in biomarker measurements. New biomarkers can revolutionize both the development and use of therapeutics but are contingent on the establishment of a concrete validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.

[1]  A Yacobi,et al.  Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies , 1991, European Journal of Drug Metabolism and Pharmacokinetics.

[2]  Jvs Gobburu.  Biomarkers in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.

[3]  Stephen L George,et al.  Statistical Issues in Translational Cancer Research , 2008, Clinical Cancer Research.

[4]  Insuk Sohn,et al.  Statistical Challenges in Preprocessing in Microarray Experiments in Cancer , 2008, Clinical Cancer Research.

[5]  Jeremy MG Taylor,et al.  Validation of Biomarker-Based Risk Prediction Models , 2008, Clinical Cancer Research.

[6]  Richard Simon,et al.  The Use of Genomics in Clinical Trial Design , 2008, Clinical Cancer Research.

[7]  J. Lasota,et al.  Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours , 2008, Histopathology.

[8]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Pezet,et al.  Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Blay,et al.  Imatinib mesilate for the treatment of gastrointestinal stromal tumour , 2008, Expert opinion on pharmacotherapy.

[11]  J Cummings,et al.  Biomarker method validation in anticancer drug development , 2008, British journal of pharmacology.

[12]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Eric Woolf,et al.  Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples , 2007, The AAPS Journal.

[14]  Surendra Bansal,et al.  Key elements of bioanalytical method validation for small molecules , 2007, The AAPS Journal.

[15]  F. Frueh,et al.  Biomarker qualification pilot process at the US Food and Drug Administration , 2007, The AAPS Journal.

[16]  F. Bertucci,et al.  A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment , 2008, BMC Cancer.

[17]  L. To,et al.  Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Veenstra,et al.  AACR–FDA–NCI cancer biomarkers collaborative , 2007, Expert review of molecular diagnostics.

[19]  E. Wardelmann,et al.  Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy , 2007, Virchows Archiv.

[20]  C. Fletcher,et al.  The role of KIT in the management of patients with gastrointestinal stromal tumors. , 2007, Human pathology.

[21]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Federico Goodsaid,et al.  Process map proposal for the validation of genomic biomarkers. , 2006, Pharmacogenomics.

[23]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[24]  S. Kingsmore.  Multiplexed protein measurement: technologies and applications of protein and antibody arrays , 2006, Nature Reviews Drug Discovery.

[25]  P. Scott Pine,et al.  Workgroup Report: Review of Genomics Data Based on Experience with Mock Submissions—View of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee , 2005, Environmental health perspectives.

[26]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[27]  R. Simon,et al.  Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients , 2005, Clinical Cancer Research.

[28]  Binodh DeSilva,et al.  Bioanalytical Method Validation for Macromolecules in Support of Pharmacokinetic Studies , 2005, Pharmaceutical Research.

[29]  H. Soares,et al.  Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report , 2005, Pharmaceutical Research.

[30]  L. Lesko,et al.  Pharmacogenomic data: FDA voluntary and required submission guidance. , 2004, Pharmacogenomics.

[31]  Carlos R Plata-Salamán,et al.  Biomarker discovery and validation: technologies and integrative approaches. , 2004, Trends in biotechnology.

[32]  R. Kerbel,et al.  Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development , 2004, Clinical Cancer Research.

[33]  Krys J. Miller,et al.  Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report , 2001, Pharmaceutical Research.

[34]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[35]  Thomas Layloff,et al.  Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies , 1992, Pharmaceutical Research.

[36]  Inder M. Verma,et al.  The NIH Roadmap , 2004 .

[37]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Zerhouni.  The NIH Roadmap , 2003, Science.

[39]  J. Ford,et al.  Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  W. Colburn,et al.  Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing , 2003, Journal of clinical pharmacology.

[41]  M. Deininger.  Cytogenetic studies in patients on imatinib. , 2003, Seminars in hematology.

[42]  E. Zerhouni,et al.  Medicine. The NIH Roadmap. , 2003, Science.

[43]  B. Druker.  Imatinib alone and in combination for chronic myeloid leukemia. , 2003, Seminars in hematology.

[44]  John A. Wagner,et al.  Overview of Biomarkers and Surrogate Endpoints in Drug Development , 2002, Disease markers.

[45]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[46]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  I. Smith,et al.  Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies , 2001, Anti-cancer drugs.

[48]  R W Veltri,et al.  Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. , 2001, Urology.

[49]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[50]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[51]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[52]  J. W. Findlay,et al.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. , 2000, Journal of pharmaceutical and biomedical analysis.

[53]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R Dybkaer,et al.  Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine. , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[55]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  W. Colburn,et al.  Surrogate Biochemical Markers: Precise Measurement for Strategic Drug and Biologics Development , 1995, Journal of clinical pharmacology.

[57]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.